Document Type
Article
Publication Date
4-25-2019
Keywords
JGM
JAX Source
Microbiome 2019 Apr 25; 7(1):66
Volume
7
Issue
1
First Page
66
Last Page
66
ISSN
2049-2618
PMID
31018870
DOI
https://doi.org/10.1186/s40168-019-0679-5
Grant
CA034196,DE021578
Abstract
BACKGROUND: Gastrointestinal mucosal injury (mucositis), commonly affecting the oral cavity, is a clinically significant yet incompletely understood complication of cancer chemotherapy. Although antineoplastic cytotoxicity constitutes the primary injury trigger, the interaction of oral microbial commensals with mucosal tissues could modify the response. It is not clear, however, whether chemotherapy and its associated treatments affect oral microbial communities disrupting the homeostatic balance between resident microorganisms and the adjacent mucosa and if such alterations are associated with mucositis. To gain knowledge on the pathophysiology of oral mucositis, 49 subjects receiving 5-fluorouracil (5-FU) or doxorubicin-based chemotherapy were evaluated longitudinally during one cycle, assessing clinical outcomes, bacterial and fungal oral microbiome changes, and epithelial transcriptome responses. As a control for microbiome stability, 30 non-cancer subjects were longitudinally assessed. Through complementary in vitro assays, we also evaluated the antibacterial potential of 5-FU on oral microorganisms and the interaction of commensals with oral epithelial tissues.
RESULTS: Oral mucositis severity was associated with 5-FU, increased salivary flow, and higher oral granulocyte counts. The oral bacteriome was disrupted during chemotherapy and while antibiotic and acid inhibitor intake contributed to these changes, bacteriome disruptions were also correlated with antineoplastics and independently and strongly associated with oral mucositis severity. Mucositis-associated bacteriome shifts included depletion of common health-associated commensals from the genera Streptococcus, Actinomyces, Gemella, Granulicatella, and Veillonella and enrichment of Gram-negative bacteria such as Fusobacterium nucleatum and Prevotella oris. Shifts could not be explained by a direct antibacterial effect of 5-FU, but rather resembled the inflammation-associated dysbiotic shifts seen in other oral conditions. Epithelial transcriptional responses during chemotherapy included upregulation of genes involved in innate immunity and apoptosis. Using a multilayer epithelial construct, we show mucositis-associated dysbiotic shifts may contribute to aggravate mucosal damage since the mucositis-depleted Streptococcus salivarius was tolerated as a commensal, while the mucositis-enriched F. nucleatum displayed pro-inflammatory and pro-apoptotic capacity.
CONCLUSIONS: Altogether, our work reveals that chemotherapy-induced oral mucositis is associated with bacterial dysbiosis and demonstrates the potential for dysbiotic shifts to aggravate antineoplastic-induced epithelial injury. These findings suggest that control of oral bacterial dysbiosis could represent a novel preventive approach to ameliorate oral mucositis.
Recommended Citation
Hong B,
Sobue T,
Choquette L,
Dupuy A,
Thompson A,
Burleson J,
Salner A,
Schauer P,
Joshi P,
Fox E,
Shin D,
Weinstock GM,
Strausbaugh L,
Dongari-Bagtzoglou A,
Peterson D,
Diaz P.
Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis. Microbiome 2019 Apr 25; 7(1):66
Comments
The authors would like to acknowledge Dr. Julia Oh (Jackson Laboratory for Genomic Medicine) for kindly providing us with the scripts and database to classify Malassezia species.
This open access article is licensed under a Creative Commons Attribution 4.0 International License.